BioCryst Pharmaceuticals | BCRX - Ordinary Share Capital


BioCryst Pharmaceuticals reported $255.26M in Ordinary Share Capital for its fiscal quarter ending in June of 2026.





Ordinary Share Capital Change Date
Alnylam Pharmaceuticals USD 133.88M 141K Sep/2026
BioCryst Pharmaceuticals USD 255.26M 42.2M Jun/2026
Chugai Pharma JPY 1.65B 0 Sep/2026
Daiichi Sankyo JPY 1.82B 1.68M Sep/2026
DBV Technologies USD 235.6M 98.78M Dec/2025
Enanta Pharmaceuticals USD 212K 1000 Dec/2023
Gilead Sciences USD 1.24B 1000K Jun/2026
GlaxoSmithKline GBP 2.02B 2.05B Sep/2026
Glaxosmithkline GBP 2.02B 2.03B Sep/2026
Incyte USD 200.98M 1.03M Jun/2026
Ionis Pharmaceuticals USD 165.64M 265K Jun/2026
Karyopharm Therapeutics USD 22.54M 4.23M Mar/2026
Neurocrine Biosciences USD 101.3M 750K Sep/2026
Novavax USD 162.58M 106K Dec/2025
PTC Therapeutics USD 83.33M 445K Jun/2026
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Roche Holding CHF 796.77M 1.15M Jun/2026
Sarepta Therapeutics USD 107.23M 1.61M Sep/2026
Ultragenyx Pharmaceutical USD 98.6M 300K Jun/2026
Vertex Pharmaceuticals USD 253.5M 200K Sep/2026